The verdict against Monsanto

A California jury has awarded $289 million to DeWayne Johnson, a groundskeeper who has non-Hodgkins lymphoma and claims his disease was caused by glyphosate, Monsanto’s blockbuster pesticide marketed most prominently as Roundup.

Michael Hiltzik of the LA Times reviews the facts of the case and the scientific dispute surrounding glyphosate’s role, or lack thereof, in causing cancer. He points out, reasonably, that a courtroom is a lousy places to resolve scientific disputes; how many of the twelve jurors could define “statistical significance” or “type II error”? And the notion that non-experts can pick out the truth in a swearing contest between experts is simply laughable.

Hilzik notes that alternatives, including “bringing these cases before specialized tribunals or setting up public funds for victims of certain products,” “all have their own flaws,” and concludes with an expert’s view that the jury trial “is a highly imperfect process,” but that “like democracy, it’s the best we have.”

I doubt it. Continue reading “The verdict against Monsanto”

Reality check

Note to climate-change deniers: Monsanto just bought Climate Corp. for $970M.

I’m not qualified to judge whether the sale of Climate Corporation to Monsanto is a Good Thing or a Bad Thing, or how much of the “Monsatan” label Monsanto has actually earned.

But I’d like to hear the climate-change deniers explain why Monsanto wanted to pay almost $1 billion for a company whose business model is protecting farmers against increasing volatility in the weather, and whose models predict that Kansas will become inhospitable to corn and Alaska a good place to grow wheat.